Trial record 3 of 3 for: A5257

Previous Study | Return to List | Next Study

Comparative Study of Three NNRTI-Sparing HAART Regimens

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00811954

Recruitment Status : Completed

First Posted : December 19, 2008

Results First Posted : September 5, 2014

Last Update Posted : September 5, 2014

Sponsor:

Collaborators:

National Institute of Allergy and Infectious Diseases (NIAID)

Bristol-Myers Squibb

Gilead Sciences

Merck Sharp & Dohme Corp.

Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Information provided by (Responsible Party):

AIDS Clinical Trials Group

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Condition:	HIV Infection
Interventions:	Drug: Emtricitabine/tenofovir disoproxil fumarate Drug: Raltegravir Drug: Darunavir Drug: Ritonavir Drug: Atazanavir

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruited at AIDS Clinical Trials Units in the United States and Puerto Rico. Recruitment occurred between May 22, 2009 (date first subject was randomized) and June 9, 2011 (date last subject was randomized).

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
1814 were randomized 1:1:1 to treatment arms A, B, and C. Results reported for 1809 eligible participants; 5 were subsequently found ineligible and excluded from all analyses.

Reporting Groups

Description

Arm A: ATV/RTV + FTC/TDF

Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.

Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)

Arm B: RAL + FTC/TDF

FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.

Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)

Arm C: DRV/RTV + FTC/TDF

FTC/TDF, darunavir (DRV), and RTV, orally, once daily.

Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)

Participant Flow: Overall Study

	Arm A: ATV/RTV + FTC/TDF	Arm B: RAL + FTC/TDF	Arm C: DRV/RTV + FTC/TDF
STARTED	605	603	601
COMPLETED	516	531	500
NOT COMPLETED	89	72	101
Death	10	6	13
Lost to Follow-up	29	23	34
Not able to get to clinic	28	35	30
Not willing to adhere to requirements	12	2	16
Withdraw consent prior study completion	4	6	5
Site Closure	4	0	1
Severe Debilitation	2	0	1
Complete Protocol: No follow-up	0	0	1

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intention to treat: All eligible participants were included in the baseline characteristics.

Reporting Groups

	Description
Arm A: ATV/RTV + FTC/TDF	Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily. Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)
Arm B: RAL + FTC/TDF	FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily. Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)
Arm C: DRV/RTV + FTC/TDF	FTC/TDF, darunavir (DRV), and RTV, orally, once daily. Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)
Total	Total of all reporting groups

Baseline Measures

Arm A: ATV/RTV + FTC/TDF

Arm B: RAL + FTC/TDF

Arm C: DRV/RTV + FTC/TDF

Total

Overall Participants Analyzed
[Units: Participants]

605

603

601

1809

Age
[Units: Participants]

<=18 years

Between 18 and 65 years

597

598

595

1790

>=65 years

Age
[Units: Years]
Mean (Standard Deviation)

38 (11)

37 (11)

38 (11)

37 (11)

Gender
[Units: Participants]

Female

144

148

143

435

Male

461

455

458

1374

Race/Ethnicity, Customized ^[1]
[Units: Participants]

White Non-Hispanic

212

191

615

Black Non-Hispanic

252

254

251

757

Hispanic (Regardless of Race)

125

117

148

390

Asian, Pacific Islander

American Indian, Alaskan Native

More than one race

Unknown/missing

^[1]	Race/Ethnicity was collected prior to study entry

HIV-1 RNA ^[1]
[Units: Log10 copies/mL]
Mean (Standard Deviation)

4.6 (0.7)

^[1]

HIV-1 RNA was calculated as the geometric mean of the two most recent HIV-1 RNA (log 10 copies/mL) obtained on or before study entry. In the event that these two values differed by more than 1log10 copy/mL, the outlying value (based on review of all HIV-1 RNA levels available prior to study entry by the study virologist) was excluded and baseline determined by the remaining sample. Note that screening HIV-1 RNA values were not sued in the calculation of baseline HIV-1 RNA levels.

CD4+ T-cell count ^[1]
[Units: Cells/mm^3]
Mean (Standard Deviation)

309 (189)

306 (199)

310 (189)

308 (192)

^[1]	CD4+ T-cell counts were calculated as the mean of the two most recent values available on or before study entry.

Outcome Measures

Show All Outcome Measures

1. Primary:

Cumulative Probability of First Virologic Failure by Week 96 [ Time Frame: From study entry to week 96 ]

Show Outcome Measure 1

2. Primary:

Cumulative Incidence of Discontinuation of the RAL or PI Component of Randomized Treatment for Toxicity by Week 96 [ Time Frame: From study entry to week 96 ]

Show Outcome Measure 2

3. Secondary:

Cumulative Incidence of First Adverse Event by Week 96 [ Time Frame: From study entry to week 96 ]

Show Outcome Measure 3

4. Secondary:

Cumulative Probability of Time to Loss of Virologic Response (TLOVR) by Week 96 [ Time Frame: From study entry to week 96 ]

Show Outcome Measure 4

5. Secondary:

Presence of Mutations Associated With NRTI Resistance [ Time Frame: At the virologic failure at any time throughout the study (up to 213 weeks) ]

Show Outcome Measure 5

6. Secondary:

Presence of Mutations Associated With ATV/RTV or DRV/RTV Resistance [ Time Frame: At the virologic failure at any time throughout the study (up to 213 weeks) ]

Show Outcome Measure 6

7. Secondary:

Presence of Mutations Associated With INI Resistance [ Time Frame: At the virologic failure at any time throughout the study (up to 213 weeks) ]

Show Outcome Measure 7

8. Secondary:

CD4+ T-cell Count [ Time Frame: At Weeks 24, 48, 96, and 144 ]

Show Outcome Measure 8

9. Secondary:

CD4+ T-cell Count Changes From Baseline [ Time Frame: Study entry to weeks 24, 48, 96, and 144 ]

Show Outcome Measure 9

10. Secondary:

Incidence of Death or AIDS Defining Events (CDC Category C) [ Time Frame: Study entry to off-study at any time throughout the study (up to 213 weeks), participant follow-up time was variable ]

Show Outcome Measure 10

11. Secondary:

Incidence of Targeted Serious Non-AIDS Defining Events (Renal Failure, Liver Disease, Serious Metabolic Disorder, and CVD) [ Time Frame: Study entry to off-study at any time throughout the study (up to 213 weeks), participant follow-up time was variable ]

Show Outcome Measure 11

12. Secondary:

Change in Fasting Total Cholesterol Level From Baseline [ Time Frame: Study entry to weeks 48, 96, and 144 ]

Show Outcome Measure 12

13. Secondary:

Change in Fasting HDL Cholesterol Level From Baseline [ Time Frame: Study entry to weeks 48, 96, and 144 ]

Show Outcome Measure 13

14. Secondary:

Change in Fasting Triglycerides Level From Baseline [ Time Frame: Study entry to weeks 48, 96, and 144 ]

Show Outcome Measure 14

15. Secondary:

Change in Fasting Plasma Glucose Level From Baseline [ Time Frame: Study entry to weeks 48, 96, and 144 ]

Show Outcome Measure 15

16. Secondary:

Change in Framingham 10-year Risk of MI or Coronary Death From Baseline [ Time Frame: Study entry to weeks 48, 96, and 144 ]

Show Outcome Measure 16

17. Secondary:

Change in Waist Circumference From Baseline [ Time Frame: Study entry to weeks 48, 96, and 144 ]

Show Outcome Measure 17

18. Secondary:

Change in Waist:Height Ratio From Baseline [ Time Frame: Study entry to weeks 48, 96, and 144 ]

Show Outcome Measure 18

19. Secondary:

Self-reported Adherence [ Time Frame: At Weeks 4, 24, 48, 96, and 144 ]

Show Outcome Measure 19

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.

Results Point of Contact:

Name/Title: ACTG Clinicaltrials.gov Coordinator
Organization: ACTG Network Coordinating Center, Social & Scientific Systems, Inc.
phone: (301) 628-3313
e-mail: ACTGCT.Gov@s-3.com

Publications:

Bartlett JA, Chen SS, Quinn JB. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. HIV Clin Trials. 2007 Jul-Aug;8(4):221-6. Review.

Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33.

Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D; CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, Kelesidis T, Rothenberg J, Stein JH, Brown TT. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clin Infect Dis. 2016 Apr 1;62(7):853-62. doi: 10.1093/cid/ciw017. Epub 2016 Jan 20.

Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dube MP, Murphy R, Yang OO, Currier JS, McComsey GA. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clin Infect Dis. 2015 Aug 15;61(4):651-60. doi: 10.1093/cid/civ327. Epub 2015 Apr 22.

Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015 Jun 15;60(12):1842-51. doi: 10.1093/cid/civ193. Epub 2015 Mar 12.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum in: Ann Intern Med. 2014 Nov 4;161(9):680.

Responsible Party:	AIDS Clinical Trials Group
ClinicalTrials.gov Identifier:	NCT00811954 History of Changes
Other Study ID Numbers:	ACTG A5257 1U01AI068636 ( U.S. NIH Grant/Contract )
First Submitted:	December 18, 2008
First Posted:	December 19, 2008
Results First Submitted:	June 23, 2014
Results First Posted:	September 5, 2014
Last Update Posted:	September 5, 2014

To Top